 PARIS and CAMBRIDGE, Mass., Aug. 02, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, Biophytis or the company is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the top line results of the SARA-INT phase 2 clinical study with Sarconeos BIO101 in Sarcopenia: 